ElliotNeilDeHaanMD

HIV/AIDS Medicine

Director Vaccine Clinical Research & Development Pfizer, Inc.

Dr. DeHaan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Elliot DeHaan, MD is an Infectious Disease specialist based in Pearl River, NY, with a subspecialty in HIV/AIDS Medicine. He gained his education from prestigious institutions such as Harvard University and NYU Grossman School of Medicine, and served in various capacities at Pfizer Inc., Weill Cornell Medicine, and SUNY Downstate Health Sciences University, among others. Dr. DeHaan has a number of published works in notable medical journals including The New England Journal of Medicine and Open Forum Infectious Diseases.

PubMed

Bivalent RSVpreF Vaccine in Adults 18 to <60 Years Old With High-Risk Conditions.
Matthew Davis, William Towner, Elliot DeHaan, Qin Jiang, Wen Li
Clinical Infectious Diseases. 2024-11-11
RENOIR Trial - RSVpreF Vaccine Efficacy over Two Seasons.
Edward E Walsh, Gonzalo Pérez Marc, Ann R Falsey, Qin Jiang, Daniel Eiras
The New England Journal of Medicine. 2024-10-17
168 citations
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.
Edward E Walsh, Gonzalo Pérez Marc, Agnieszka M Zareba, Ann R Falsey, Qin Jiang
The New England Journal of Medicine. 2023-04-20